ADP-ribosyltransferases, an update on function and nomenclature

Research output: Contribution to journalJournal articleResearchpeer-review


  • Fulltext

    Final published version, 1.07 MB, PDF document

  • Bernhard Lüscher
  • Ivan Ahel
  • Matthias Altmeyer
  • Alan Ashworth
  • Peter Bai
  • Paul Chang
  • Michael Cohen
  • Daniela Corda
  • Françoise Dantzer
  • Matthew D. Daugherty
  • Ted M. Dawson
  • Valina L. Dawson
  • Sebastian Deindl
  • Anthony R. Fehr
  • Karla L.H. Feijs
  • Dmitri V. Filippov
  • Jean Philippe Gagné
  • Giovanna Grimaldi
  • Sebastian Guettler
  • Nicolas C. Hoch
  • Michael O. Hottiger
  • Patricia Korn
  • W. Lee Kraus
  • Andreas Ladurner
  • Lari Lehtiö
  • Anthony K.L. Leung
  • Christopher J. Lord
  • Aswin Mangerich
  • Ivan Matic
  • Jason Matthews
  • George Lucian Moldovan
  • Joel Moss
  • Gioacchino Natoli
  • Mario Niepel
  • Friedrich Nolte
  • John Pascal
  • Bryce M. Paschal
  • Krzysztof Pawłowski
  • Guy G. Poirier
  • Susan Smith
  • Gyula Timinszky
  • Zhao Qi Wang
  • José Yélamos
  • Xiaochun Yu
  • Roko Zaja
  • Mathias Ziegler

ADP-ribosylation, a modification of proteins, nucleic acids, and metabolites, confers broad functions, including roles in stress responses elicited, for example, by DNA damage and viral infection and is involved in intra- and extracellular signaling, chromatin and transcriptional regulation, protein biosynthesis, and cell death. ADP-ribosylation is catalyzed by ADP-ribosyltransferases (ARTs), which transfer ADP-ribose from NAD+ onto substrates. The modification, which occurs as mono- or poly-ADP-ribosylation, is reversible due to the action of different ADP-ribosylhydrolases. Importantly, inhibitors of ARTs are approved or are being developed for clinical use. Moreover, ADP-ribosylhydrolases are being assessed as therapeutic targets, foremost as antiviral drugs and for oncological indications. Due to the development of novel reagents and major technological advances that allow the study of ADP-ribosylation in unprecedented detail, an increasing number of cellular processes and pathways are being identified that are regulated by ADP-ribosylation. In addition, characterization of biochemical and structural aspects of the ARTs and their catalytic activities have expanded our understanding of this protein family. This increased knowledge requires that a common nomenclature be used to describe the relevant enzymes. Therefore, in this viewpoint, we propose an updated and broadly supported nomenclature for mammalian ARTs that will facilitate future discussions when addressing the biochemistry and biology of ADP-ribosylation. This is combined with a brief description of the main functions of mammalian ARTs to illustrate the increasing diversity of mono- and poly-ADP-ribose mediated cellular processes.

Original languageEnglish
JournalFEBS Journal
Issue number23
Pages (from-to)7399-7410
Publication statusPublished - 2022

Bibliographical note

Publisher Copyright:
© 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

    Research areas

  • ADP-ribosylation, MARylation, PARP, PARylation, posttranslational modification

ID: 280173076